BIO-TECHNE Corp

TECH - CIK 0000842023

Market cap$8.22 B

Rank#1055

SEC filings1,229

BIO-TECHNE Corp trades as TECH and has a market capitalization of $8.22 B, making it the #1055 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.22B, up 5.2% from the prior year and net income of $73.40M. This page tracks BIO-TECHNE Corp through 1,229 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.22BFY 2025

Net income (latest FY)$73.40MFY 2025

Operating cash flow (latest FY)$287.56MFY 2025

Total assets (latest FY)$2.56BFY 2025

Gross margin64.8%latest FY

Net margin6.0%latest FY

Financial performance

Over the last 9 fiscal years BIO-TECHNE Corp's revenue grew from $499.02M to $1.22B, a compound annual growth rate of 10.4%. Net profit margin compressed from 20.9% to 6.0% over the same period - every figure below comes from the company's audited annual filings.

TECH annual revenueView details

Key statistics

Market cap: $8.22 B
Share price (derived)market cap / shares outstanding: $52.50
P/E ratio (trailing FY): 112.0
EPS (diluted)FY 2025: $0.46
Shares outstandingas of 2026-04-29: 0.16B
Total equityas of 2026-03-31: $2.09B
Return on equity: 3.5%
Cash & equivalentsas of 2026-03-31: $209.82M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-12
Insider sale notice	144	2026-05-08
Insider trade	4	2026-05-07
Insider trade	4	2026-05-07
Insider trade	4	2026-05-07
Quarterly report	10-Q	2026-05-06
Major company event	8-K	2026-05-06
SCHEDULE 13G	-	2026-05-06

Browse the full filing history (1,229 filings)

Recent press releases

Bio-Techne Declares Dividend2026-05-06
Bio-Techne Declares Dividend :: Bio-Techne Corporation (TECH)
Bio-Techne Releases Third Quarter Fiscal 2026 Results2026-05-06
Bio-Techne Releases Third Quarter Fiscal 2026 Results :: Bio-Techne Corporation (TECH)
Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference2026-05-04
Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference :: Bio-Techne Corporation (TECH)
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity2026-04-16
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity :: Bio-Techne Corporation (TECH)
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results2026-04-14
Access to the discussion may be obtained as follows:

Similar companies

The largest companies sharing BIO-TECHNE Corp's SEC industry classification (biological products, (no diagnostic substances)).

AMGNAmgen Inc.$183.41 B TECH vs AMGN

GILDGilead Sciences, Inc.$151.05 B TECH vs GILD

ARGXargenx SE$53.35 B TECH vs ARGX

RVMDRevolution Medicines, Inc.$30.65 B TECH vs RVMD

BIIBBiogen Inc.$28.68 B TECH vs BIIB

Frequently asked questions

What is BIO-TECHNE Corp's market cap?

BIO-TECHNE Corp (TECH) has a market capitalization of $8.22 B as of 2026-06-10, ranking #1055 among US-listed companies.

How much revenue does BIO-TECHNE Corp make?

BIO-TECHNE Corp reported revenue of $1.22B for fiscal year 2025, an increase of 5.2% year over year.

Is BIO-TECHNE Corp profitable?

Yes. BIO-TECHNE Corp reported net income of $73.40M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.